P1213: SUBCUTANEOUS EPCORITAMAB WITH GEMOX INDUCED HIGH RESPONSE RATES IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA INELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANT

• B. E. Wahlin,
• J. Brody,
• T. Phillips,
• R. Costello,
• P. Lugtenburg,
• R. Cordoba,
• L. Wang,
• J. Wu,
• B. Elliott,
• A. Abbas,
• J. Jørgensen

Affiliations

B. E. Wahlin

1 Karolinska Institutet, Stockholm, Sweden

J. Brody

2 Icahn School of Medicine at Mount Sinai, New York

T. Phillips

3 University of Michigan Comprehensive Cancer Center, Ann Arbor, United States of America

R. Costello

4 Assistance Publique – Hôpitaux de Marseille (AP-HM), Marseille, France

P. Lugtenburg

5 Department of Hematology, On behalf of the Lunenburg Lymphoma Phase I/II Consortium-HOVON/LLPC, Erasmus MC Cancer Institute, Rotterdam, Netherlands

R. Cordoba

6 Fundacion Jimenez Diaz University Hospital, Health Research Institute IIS-FJD, Madrid, Spain

L. Wang

7 Genmab, Princeton

J. Wu

8 AbbVie, North Chicago, United States of America

B. Elliott

7 Genmab, Princeton

A. Abbas

7 Genmab, Princeton

J. Jørgensen

9 Aarhus University Hospital, Aarhus, Denmark